Skip to main content
. Author manuscript; available in PMC: 2023 Jan 12.
Published in final edited form as: Nano Lett. 2021 Oct 20;22(1):533–542. doi: 10.1021/acs.nanolett.1c02503

Figure 3.

Figure 3.

Dose–response of top-performing LNPs from libraries A and B confirm enhanced mRNA delivery to a T cell line (Jurkat) over a standard LNP formulation and lipofectamine. (A) Luciferase expression and viability of Jurkat cells treated with S2, A16, or B10 LNPs for 48 h, confirming the relative performance of each formulation. Luminescence and viability were normalized to untreated cells and compared within each dose using a one-way ANOVA with post hoc t tests using Holm’s correction. *p < 0.05, ***p < 0.001 as compared to S2, n = 3 biological replicates, error bars = standard deviation. (B) Luciferase expression and viability of Jurkat cells treated with B10 LNPs or lipofectamine for 48 h showing the ability of B10 LNPs to achieve increased mRNA delivery with no increase in cytotoxicity. Luminescence and viability were normalized to untreated cells, and the treatment groups were compared within each dose using a t test with post hoc t tests using Holm’s correction. **p < 0.01, n = 3 biological replicates, error bars = standard deviation.